Document:

<Page>

                                                                   Exhibit 10.19
                              CONSULTING AGREEMENT

     THIS CONSULTING AGREEMENT (the "Agreement"), made this 27th day of October,
2003, is entered into by NITROMED INC., a Delaware corporation having a
principal place of business at 12 Oak Park Drive, Bedford, MA 01730 (the
"Company"), and JOSEPH LOSCALZO, M.D., PH. D., Boston University of
Massachusetts, Boston Medical Center, 720 Harrison Avenue, Suite 402, Boston, MA
02118 (the "Consultant").

                                  INTRODUCTION

     The Company desires to retain the services of the Consultant and the
Consultant desires to perform certain services for the Company. In consideration
of the mutual covenants and promises contained herein and other good and
valuable consideration, the receipt and sufficiency of which is hereby
acknowledged by the parties hereto, the parties agree as follows:

     1. SERVICES. The Consultant agrees to perform such consulting, advisory and
related services to and for the Company as may be reasonably requested from time
to time by the Company. These services include those required as a Chairman of
NitroMed's Scientific Advisory Board. During the Consultation Period (as defined
below), the Consultant shall not engage in any activity that has a conflict of
business interest with the Company, without prior disclosure to the Company.

     2. TERM.

        2.1 INITIAL TERM. The initial term of this Agreement is for ten (10)
calendar years shall commence on October 1, 2003, and shall expire on
September 30, 2013 (such period, as it may be extended, being referred to as
the "Consultation Period"), unless sooner terminated in accordance with the
provisions of Section 4.

        2.2 TERM EXTENSION. This Agreement may be extended for additional
periods of two (2) calendar years each if Company gives Consultant written
notice of such extension at least sixty (60) days prior to the expiration date
of the initial term. Company may not extend this Agreement more than five (5)
times. The terms and conditions of this Agreement shall remain the same during
each extension period.

     3. COMPENSATION.

        3.1 CONSULTING FEES. The Company shall pay to the Advisor an annual
advisory fee of $70,000.00, payable quarterly in arrears.

        3.2 BENEFITS. The Consultant shall not be entitled to any benefits,
coverages or privileges, including, without limitation, social security,
unemployment, medical or pension payments, made available to employees of the
Company.

        4. TERMINATION. The Company may, without prejudice to any right or
remedy it may have due to any failure of the Consultant to perform his
obligations under this Agreement,

<Page>

terminate the Consultation Period upon 30 days' prior written notice to the
Consultant. Notwithstanding the foregoing, the Company may terminate the
Consultation Period, effective immediately upon receipt of written notice, if
the Consultant breaches or threatens to breach any provision of Section 6.

     5. COOPERATION. The Consultant shall use his best efforts in the
performance of his obligations under this Agreement. The Company shall provide
such access to its information and property as may be reasonably required in
order to permit the Consultant to perform his obligations hereunder. The
Consultant shall cooperate with the Company's personnel, shall not interfere
with the conduct of the Company's business and shall observe all rules,
regulations and security requirements of the Company concerning the safety of
persons and property.

     6. INVENTIONS AND PROPRIETARY INFORMATION.

        6.1 INVENTIONS.

            All inventions, discoveries, computer programs, data, technology,
designs, innovations and improvements (whether or not patentable and whether or
not copyrightable) ("Inventions") related to the business of the Company which
are made, conceived, reduced to practice, created, written, designed or
developed by the Consultant, solely or jointly with others and whether during
normal business hours or otherwise, during the Consultation Period or thereafter
if resulting or directly derived from Proprietary Information (as defined
below), shall be the sole property of the Trustees of Boston University (the
"University"). All Inventions related to the business of the Company and any and
all related patents, copyrights, trademarks, trade names, and other industrial
and intellectual property rights and applications therefore, in the United
States and elsewhere, shall be assigned to the University pursuant to the patent
policy of the University and the Research and License Agreement between the
University and NitroMed, Inc., effective June 1, 1993.

        6.2 PROPRIETARY INFORMATION.

            (a) The Consultant acknowledges that his relationship with the
Company is one of high trust and confidence and that in the course of his
service to the Company he will have access to and contact with Proprietary
Information. The Consultant agrees that he will not, during the Consultation
Period or at any time thereafter, disclose to others, or use for his benefit or
the benefit of others, any Proprietary Information or Invention.

            (b) For purposes of this Agreement, Proprietary Information shall
mean, by way of illustration and not limitation, all information (whether or not
patentable and whether or not copyrightable) owned, possessed or used by the
Company, including, without limitation, any Invention, formula, vendor
information, customer information, apparatus, equipment, trade secret, process,
research, report, technical data, know-how, computer program, software, software
documentation, hardware design, technology, marketing or business plan,
forecast, unpublished financial statement, budget, license, price, cost and
employee list that is communicated to, learned of, developed or otherwise
acquired by the Consultant in the course of his service as a consultant to the
Company.

<Page>

            (c) The Consultant's obligations under this Section 6.2 shall not
apply to any information that (i) is or becomes known to the general public
under circumstances involving no breach by the Consultant or others of the terms
of this Section 6.2, (ii) is generally disclosed to third parties by the Company
without restriction on such third parties, or (iii) is approved for release by
the Company.

            (d) Upon termination of this Agreement or at any other time upon
request by the Company, the Consultant shall promptly deliver to the Company
copies of all related files, memoranda, data, reports, and other documents
relating to the projects funded by the Company.

            (e) The Consultant represents that his retention as a consultant
with the Company and his performance under this Agreement does not, and shall
not, breach any agreement that obligates him to keep in confidence any trade
secrets or confidential or proprietary information of his or of any other party
or to refrain from competing, directly or indirectly, with the business of any
other party. The Consultant shall not disclose to the Company any trade secrets
or confidential or proprietary information of any other party.

            (f) The Consultant acknowledges that the Company from time to time
may have agreements with other persons or with the United States Government, or
agencies thereof, that impose obligations or restrictions on the Company
regarding inventions made during the course of work under such agreements or
regarding the confidential nature of such work. The Consultant agrees to be
bound by all such obligations and restrictions that are known to him and to take
all action necessary to discharge the obligations of the Company under such
agreements.

        6.3 REMEDIES. The Consultant acknowledges that any breach of the
provisions of this Section 6 shall result in serious and irreparable injury to
the Company. The Consultant agrees that the Company shall be entitled to seek
both temporary and permanent injunctive relief.

     7. INDEPENDENT CONTRACTOR STATUS. The Consultant shall perform all services
under this Agreement as an "independent contractor" and not as an employee or
agent of the Company. The Consultant is not authorized to assume or create any
obligation or responsibility, express or implied, on behalf of, or in the name
of, the Company or to bind the Company in any manner.

     8. NOTICES. All notices required or permitted under this Agreement shall be
in writing and shall be deemed effective upon personal delivery or upon deposit
in the United States Post Office, by registered or certified mail, postage
prepaid, addressed to the other party at the address shown above, or at such
other address or addresses as either party shall designate to the other in
accordance with this Section 8.

     9. PRONOUNS. Whenever the context may require, any pronouns used in this
Agreement shall include the corresponding masculine, feminine or neuter forms,
and the singular forms of nouns and pronouns shall include the plural, and vice
versa.

<Page>

     10. ENTIRE AGREEMENT. This Agreement constitutes the entire agreement
between the parties and supersedes all prior agreements and understandings,
whether written or oral, relating to the subject matter of this Agreement.

     11. AMENDMENT. This Agreement may be amended or modified only by a written
instrument executed by both the Company and the Consultant.

     12. GOVERNING LAW. This Agreement shall be construed, interpreted and
enforced in accordance with the laws of the Commonwealth of Massachusetts.

     13. SUCCESSORS AND ASSIGNS. This Agreement shall be binding upon, and inure
to the benefit of, both parties and their respective successors and assigns,
including any corporation with which, or into which, the Company may be merged
or which may succeed to its assets or business, provided, however, that the
obligations of the Consultant are personal and shall not be assigned by him.

     14. MISCELLANEOUS.

        14.1 No delay or omission by the Company in exercising any right under
this Agreement shall operate as a waiver of that or any other right. A waiver or
consent given by the Company on any one occasion shall be effective only in that
instance and shall not be construed as a bar or waiver of any right on any other
occasion.

        14.2 The captions of the sections of this Agreement are for convenience
of reference only and in no way define, limit or affect the scope or substance
of any section of this Agreement.

        14.3 In the event that any provision of this Agreement shall be invalid,
illegal or otherwise unenforceable, the validity, legality and enforceability of
the remaining provisions shall in no way be affected or impaired thereby.
IN WITNESS WHEREOF, the parties hereto have
executed this Agreement as of the day and year set forth above.

                                            NITROMED INC.

                                            By: /s/ L. Gordon Letts
                                                ----------------------
                                                L. Gordon Letts, Ph.D.

                                            Title:   Senior VP R&D, CSO
JOSEPH LOSCALZO

By:  /s/ Joseph Loscalzo
     -------------------
     Joseph Loscalzo, M.D. Ph.D

Social Security No.:

xxx-xx-xxxx

<Page>

                     AMENDMENT NO. 1 TO CONSULTING AGREEMENT

     This Amendment No. 1, effective as of the 1st day of April, 2004, amends
the Consulting Agreement (the "Agreement") dated October 27, 2003, between
NITROMED INC., a Delaware corporation having a principal place of business at
12 Oak Park Drive, Bedford, MA 01730 (the "Company"), and JOSEPH LOSCALZO,
M.D., PH.D., Boston University of Massachusetts, Boston Medical Center, 720
Harrison Avenue, Suite 402, Boston, MA 02118 (the "Consultant").

     In consideration of the terms and conditions set forth in the Agreement,
and other good and valuable consideration, the receipt and sufficiency of which
are hereby acknowledged, the Consultant and the Company agree that Section 3.1
of the Agreement is hereby deleted and the following is inserted in lieu
thereof:

     "3.1 Consulting Fees. The Company shall pay to the Consultant an annual
advisory fee of $55,000.00, payable quarterly in arrears."

     IN WITNESS WHEREOF, the parties have executed this Agreement as of the day
and year set forth above.

                                            NITROMED INC.

                                            By: /s/ L. Gordon Letts, Ph.D.
                                                --------------------------
                                                L. Gordon Letts, Ph.D.

                                            Title: Senior VP R&D, CSO

JOSEPH LOSCALZO

By:/s/ Joseph Loscalzo, M.D., Ph.D.
   --------------------------------
   Joseph Loscalzo, M.D., Ph.D.

Social Security No.: xxx-xx-xxxx<Page>

                                                                   Exhibit 10.22
September 3, 2004

James G. Ham, III
31 Merion Place
Lawrenceville, New Jersey 08648

Dear Jim:

I would like to formally offer you the position of Vice President, Finance at
NitroMed reporting to the Chief Financial Officer and Chief Business Officer.

The terms of this offer are as follows:

Responsibilities:          You will be responsible for all controller-related
                           functions, including general accounting and auditing
                           financial control as well as financial
                           analysis/analytical support of all departments.

Base Salary:               $180,000 per year paid in 24 equal payments to be
                           reviewed annually.

Stock:                     You will be offered an option to purchase 40,000
                           shares of common stock in the Company. The price at
                           which the stock closes on your start date will be the
                           exercise price of these options. These options will
                           vest over four years in equal installments as long as
                           you remain in the employ of the Company.

Performance Bonus:         You may be entitled to receive a bonus under the
                           NitroMed bonus plan, which is discretionary and
                           based on milestones to be determined and mutually
                           agreed upon by the Chief Financial Officer/Chief
                           Business Officer and you. You will be entitled to
                           receive a minimum guaranteed first year bonus of
                           20% that will be prorated for the months remaining
                           between your date of hire and December 31, 2004.
                           Such bonus may be subject to an upward adjustment
                           in 2004, depending on performance.

Group Benefits:            You will receive comprehensive group health,
                           disability, accident and life insurance benefits or
                           such comparable benefits and protections the Company
                           is able to reasonably obtain from another plan.
                           You will be entitled to participate in and enjoy the
                           benefits of NitroMed's 401K retirement plan as well
                           as any other retirement and pension plan or plans
                           if and when instituted by the Company for the
                           benefit of its employees generally.

<Page>

James G. Ham, III
September 3, 2004
Page Two

Leave:                     You will be entitled to illness and vacation days
                           consistent with the Company's standard policy. This
                           policy provides up to three weeks vacation per
                           calendar year accrued at a rate of 1.25 days per
                           month of employment and 20 days per calendar year
                           after five years of employment.

Relocation:                Subject to your continued employment the Company will
                           reimburse you Up to a sum not to exceed $30,000 for
                           moving your household contents, including buy and
                           sell side costs such as commissions and fees. You
                           will 12 months to exercise this relocation benefit.
                           You will also be entitled to six months of temporary
                           housing reimbursable at $3,000 per month. At your
                           request, the Company will pay directly all of the
                           deductible relocation and temporary housing expenses
                           for you.

Signing Bonus:             You will be entitled to receive a $20,000 signing
                           bonus payable on January 1st 2005 dependent on your
                           continued employment.

Severance:                 You will be eligible for six months of severance if
                           you are terminated for reasons other than for cause,
                           including corporate, reorganization, merger or
                           consolidation.

Agreements:                As a condition of employment, you will be required to
                           sign the Company's assignment of invention,
                           non-disclosure, and non-compete agreements.

The commencement date for this position is on or before September 13, 2004.
Please sign a copy of this letter and return it as acceptance of this offer by
September 9, 2004.

Jim, we look forward to working with you at NitroMed. It is my wish that this
position allows you to participate in the success of NitroMed and will both
enrich and enhance your career experience.

Sincerely,

/s/ Michael D. Loberg
---------------------
Michael D. Loberg

                                    Agreed and Accepted:

                                    /s/ James G. Ham, III
                                    ---------------------
                                    James G. Ham, III

                                    Dated: September 3, 2004
                                           -----------------

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00079-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00079-of-00352.parquet"}]]